The American Diabetes Association (ADA) recommends the use of SGLT2 inhibitors in patients with established atherosclerotic cardiovascular disease, high CV risk, heart failure, or chronic kidney disease regardless of HbA1c levels [11]. This evidence concerns the gene SLC5A2 and heart failure.